Loading ...
Sorry, an error occurred while loading the content.

Fw: NATAP: HCV & HBV EASL Liver Coverage

Expand Messages
  • alleypat
    ... From: nataphcv@natap.org To: hiv@natap.org ; nataphcvhiv@natap.org ; nataphcv@natap.org ; natapindustry@natap.org ; natapdoctors@natap.org Sent: Monday,
    Message 1 of 1 , Apr 30, 2007
    • 0 Attachment
      ----- Original Message -----
      From: nataphcv@...
      To: hiv@... ; nataphcvhiv@... ; nataphcv@... ; natapindustry@... ; natapdoctors@...
      Sent: Monday, April 30, 2007 8:53 AM
      Subject: NATAP: HCV & HBV EASL Liver Coverage


      NATAP http://natap.org/
      _______________________________________________



      --------------------------------------------------------------------------------


      EASL
      42st Meeting of the European Association for the Study of Liver Diseases
      April 11-15, 2007
      Barcelona, Spain
      Â
      â?¢ R1479 (R1626), a Novel Hepatitis C Polymerase Inhibitor: Lack of Pre-Existing Resistance Mutations Supports the Observed In Vivo High Barrier to Resistance - (04/27/07)
      Â
      â?¢ ITMN-191 CONCENTRATIONS ACHIEVED IN THE LIVER OF ANIMALS PROMOTE HCV REPLICON CLEARANCE IN VITRO AND THIS EFFECT IS ENHANCED BY PEG-IFN a-2a (Pegasys) - (04/27/07)
      Â
      â?¢ HCV Protease Inhibitor ITMN-191 Resistance - (04/27/07)
      Â
      â?¢ HCV Protease Inhibitor ITMN-191 + HCV Polymerase Inhibitor R1626 Synergy - (04/27/07)
      Â
      â?¢ Lipid steatosis, metabolic variables and body composition in the setting of HIV/HCV coinfection; findings from a large randomised trial (APRICOT) - (04/26/07)
      Â
      â?¢ 400,000 IU/mL Is New Cut-Off for Low vs High Viral Load in HCV - (04/26/07)
      Â
      â?¢ Favorable Cross-Resistance Profile of Two Novel Hepatitis C Virus Inhibitors, SCH 503034 (Boceprevir) and HCV-796, and Enhanced Anti-Replicon Activity Mediated by the Combined Use of Both Compounds - (04/26/07)
      Â
      â?¢ SCH503034 & NM283 Not Cross-Resistant - (04/26/07)
      Â
      â?¢ An open label, comparative, multi-center study of peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin in the treatment of patients with chronic hepatitis C/hepatitis B dual infection versus with mono-infected chronic hepatitis C: An interim report - (04/25/07)
      Â
      â?¢ Virological response at 4 and 12 weeks predict high rates of sustained virological response in genotype 1 patients treated with peginterferon alfa-2a (40KD) plus ribavirin - (04/25/07)
      Â
      â?¢ EFFECTS OF INSULIN SENSITIZING AGENTS IN NONALCOHOLIC FATTY LIVER DISEASE, METABOLICS: metformin, rosiglitazone, metformin+rosiglitazone - (04/23/07)
      Â
      â?¢ In vitro Resistance Selection to the HCV Nucleoside Polymerase Inhibitor R1479 (R1626) and to the Protease Inhibitor VX-950 - (04/23/07)
      Â
      â?¢ HCV SVR Durable (99%) After 5 Years of Followup - (04/23/07)
      Â
      â?¢ 48 Weeks & High Ribavirin Dose May Improve SVR Rates for Genotype 2/3, French study by Bernard Willems - (04/23/07)
      Â
      â?¢ In Patients Who Clear HCV RNA At Week 12 (between week 8 and 12): SVR is Higher After 72 Weeks Than After 48 Weeks Treatment: Results of a Randomized Controlled Trial - (04/23/07)
      Â
      â?¢ New HCV Drug Target NS4A Antagonists - (04/23/07)
      Â
      â?¢ 76 Week Follow-up of HBeAg-Positive Chronic Hepatitis B Patients Treated with Telbivudine, Adefovir or Switched from Adefovir to Telbivudine - (04/23/07)
      Â
      â?¢ HBV rtI233V Polymerase Variant Remains Sensitive to Adefovir - (04/23/07)
      Â
      â?¢ Pegasys Superior to Lamivudine Over 3 Years in HBV DNA Decline, ALT Normalization & HBsAg Loss (8% vs 0) & Seroconversion (4% vs 0) - (04/23/07)
      Â
      â?¢ Peginterferon a-2a Plus adefovir vs Peginterferon a-2a for 48 Weeks in HBeAg-Negative Chronic Hepatitis B: Preliminary 24-Week Results of the PEG FOR B Randomized Multicenter Trial - (04/23/07)
      Â
      â?¢ 3 YEARS OF ADEFOVIR AND LAMIVUDINE COMBINATION THERAPY MINIMIZES THE RISK OF GENOTYPIC RESISTANCE TO ADV IN LAM RESISTANT PATIENTS - (04/20/07)
      Â
      â?¢ 14 Weeks vs 24 Weeks Peg/RBV for Genotypes 2/3 - (04/20/07)
      Â
      â?¢ CANNABIS USE AS AN INDEPENDENT PREDICTOR OF SEVERE STEATOSIS DURING CHRONIC HEPATITIS C - (04/19/07)
      Â
      â?¢ Efficacy of Entecavir and Lamivudine in Chronic Hepatitis B Patients with Advanced Liver Fibrosis/Cirrhosis - (04/19/07)
      Â
      â?¢ Presence of Biopsy-Proven Histologic Damage (Necroinflammation and Fibrosis) is Common even when ALT is less than 2 X ULN in Patients with Chronic Hepatitis B - (04/19/07)
      Â
      â?¢ Abbott HCV Polymerase Inhibitor - (04/18/07)
      Â
      â?¢ 3-Drug HCV therapy for 12 weeks: VX950+pegIFN+RBV, interim results from phase II PROVE 1 Trial - (04/17/07)
      Â
      â?¢ HCV-796 Polymerase Inhibitor Shows 1.5 log Viral Load Reduction - (04/17/07)
      Â
      â?¢ GSK625433: A Novel and Highly potent Inhibitor of the HCV NS5B Polymerase - (04/17/07)
      Â
      â?¢ Merck HCV Protease & Polymerase Inhibitor Viral Load Reduction & Resistance in Chimps - (04/17/07)
      Â
      â?¢ GSK625433: A Novel and Highly Potent Inhibitor of the HCV NS5B Polymerase - (04/17/07)
      Â
      â?¢ Interim Results Presented at EASL from PROVE 1 Clinical Trial of Investigational Drug Telaprevir in Patients with Genotype 1 Hepatitis C - (04/17/07)
      Â
      â?¢ New HCV Drug Target NS4A Antagonists - (04/17/07)
      Â
      â?¢ Entecavir (ETV) Results in Higher HBV-DNA Reduction vs Adefovir (ADV) in Chronically Infected HBeAg(+) Antiviral-Naive Adults: 48-Wk Results (E.A.R.L.Y. Study) - (04/17/07)
      Â
      â?¢ Four Year Assessment Of Entecavir Resistance In Nucleoside Naive and Lamivudine Refractory Patients - (04/17/07)
      Â
      â?¢ Four-Year Data Demonstrate Continued Low Incidence of BARACLUDE (entecavir) Resistance in Nucleoside-naive Chronic Hepatitis B Patients (press release from BMS) - (04/17/07)
      Â
      â?¢ BARACLUDE (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment (press release from BMS) - (04/17/07)
      Â
      â?¢ ETV Re-treatment of Nucleoside-Naive HBeAg(-) Patients with Recurrent Viremia - (04/17/07)
      Â
      â?¢ NM283 in Treatment-Naives Looks Better - (04/13/07)
      Â
      â?¢ NM283, HCV Polymerase Inhibitor in Non-Responders - (04/13/07)
      Â
      â?¢ Resistance to New HCV Antivirals - (04/12/07)
      Â
      â?¢ Vertex Pharmaceuticals Announces New Data for Investigational HCV Protease Inhibitor Telaprevir to be Presented at 42nd Annual Meeting of the European Association for the Study of the Liver (EASL) - (04/12/07)
      Â
      â?¢ New Clinical Study Results Indicate Higher Early Virologic Response with Celgosivir Combination Therapy in HCV Non-Responders - (04/12/07)
      Â


      Â




      **************************************
      See what's free at http://www.aol.com


      --------------------------------------------------------------------------------


      _______________________________________________
      NATAP nataphcv mailing list -- nataphcv@...

      This is an annoucement-only mailing list. Do not reply.

      To unsubscribe: send a blank email to nataphcv-request@... with a subject of unsubscribe.


      For more information, see http://seven.pairlist.net/mailman/listinfo/nataphcv

      _______________________________________________



      --------------------------------------------------------------------------------


      No virus found in this incoming message.
      Checked by AVG Free Edition.
      Version: 7.5.467 / Virus Database: 269.6.2/780 - Release Date: 4/29/2007 6:30 AM


      [Non-text portions of this message have been removed]
    Your message has been successfully submitted and would be delivered to recipients shortly.